The planned global multicenter, randomized, double blind, placebo controlled, parallel group study will evaluate the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with acute myocardial infarction.

The planned global multicenter, randomized, double blind, placebo controlled, parallel group study will evaluate the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with chronic heart failure.